Map of Pancreatica Walks and Runs

BRCA Gene Mutations and Risk of Pancreatic Cancer

BRCA1 and BRCA2 genes are important in the repair and upkeep of DNA. Mutations in these genes confer a strong tendency to not only more widely known breast cancer, but to other kinds of cancers as well – including contributing to some amount of pancreatic cancer.

 

Now, researchers from the Women’s College Research Institute, Familial Breast Cancer Research in Toronto, Canada have published a study in the British Journal of Cancer which has attempted to quantify this increased risk.

Huzarski and colleagues followed women with either an identified BRCA1 or a BRCA2 mutation, and reviewed pedigrees.  They found that the risk of either mutation increased the risk of acquiring pancreatic cancer to about double of that of the risk of the general population.

 

 

More here

 

Dale O’Brien, MD

 

 

Watchful Waiting for Small Nonfunctioning Pancreatic Neuroendocrine Tumors ?

Neuroendocrine tumors can roughly be divided into functioning and non-functioning categories. The functioning tumors produce an abundance of a given hormone such that the clinical effects of this overabundance can be observed or felt by physicians and/or patients. Non-functioning neuroendocrine tumors produce no hormone, or produce such hormones in sub-clinical quantity, or produce hormones which are not presently known and in which there is no apparent clinical effect.

 

Surgical researchers from the Mayo Clinic in the journal Surgery have published their results of a decade long study based on comparing non-surgical “watchful waiting” of almost eighty patients with small non-functioning pancreatic neuroendocrine tumors with the outcomes of 56 patients who were treated with surgery. Subjects were included in the study if their tumor was less than four centimeters in diameter without any apparent metastases or other evidence of spread.

 

They found that the watchful observation approach was worth advocating when interval radiographic studies show no or small growth or change of a solitary pancreatic neuroendocrine tumor, which they observed was quite frequent.

 

 

More here

 

Dale O’Brien, MD

 

 

Lack of Pancreatic Cancer Radiologic Improvement May NOT be an Accurate Measure of Neoadjuvant Success – an important and intriguing finding.

Researchers from the University of Texas / MD Anderson Cancer Center published an interesting recent study in the journal Cancer on the treatment and assessment of so-called neoadjuvant therapy in borderline resectable pancreatic cancer.

 

“Neoadjuvant” is a word that denotes typically the medical and/or radiological treatment of pancreatic cancer BEFORE surgery.  The term “adjuvant” refers typically to the medical and/or radiological treatment of pancreatic cancer AFTER surgery.

 

As those patients who are eligible and receive the surgery option for pancreatic cancer tend to do better than those who are not so eligible, it has seemed logical to see if there are ways to increase the number of patients who are eligible for surgery.

 

The physicians at MD Anderson Cancer Center (and other noted institutions) have been at the forefront of giving this neoadjuvant therapy – to see if there will be a radiologic response such that some percentage of those previously not eligible for surgery – would now be.  And further, if they now are finally eligible for surgery – do these patients do as well as those who were eligible from the beginning?   (It appears, with caveats – that they tend to do as well).

 

The UNEXPECTED finding reported out in this study is different, however !  The researchers looked at 129 patients who met criteria from 2005 until 2010 at their institution.  They found that although 69% of those patients with borderline surgical criteria who had received neoadjuvant therapy underwent surgery, only 1% had had their disease downstaged to resectable by radiological standards.

 

They then looked at outcomes and found that those who had received the surgery tended to live longer.

 

The rather astounding conclusion is that borderline resectable patients treated with neoadjuvant therapy without subsequent radiological evidence of downstaging should probably receive surgery anyway, in the absence of metastases.

 

This important conclusion will need to be substantiated by further studies.

 

 

More here

 

 

Dale O’Brien, MD

 

 

Page 24 of 32« First...10...2223242526...30...Last »